• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Blood test enhances early detection of pancreatic cancer

July 12, 2017 By Sarah Faulkner

Pancreatic cancer
Credit: Ken Zaret, Perelman School of Medicine, University of Pennsylvania

Researchers from the University of Pennsylvania have devised a biomarker panel that could enable earlier diagnosis and better treatment for patients with pancreatic cancer, according to a study published in Science Translational Medicine.

Pancreatic cancer is the fourth leading cause of cancer death in the U.S., the team reported, and often patients are not diagnosed until an advanced stage. At that point, their tumors can’t be removed surgically.

“Starting with our cell model that mimics human pancreatic cancer progression, we identified released proteins, then tested and validated a subset of these proteins as potential plasma biomarkers of this cancer,” lead author Ken Zaret said in prepared remarks.

The team suggested that healthcare workers could use the biomarker panel to test for the presence and levels of these proteins in blood from pancreatic cancer patients or from individuals at a high risk of developing the deadly disease.

“Early detection of cancer has had a critical influence on lessening the impact of many types of cancer, including breast, colon, and cervical cancer. A long standing concern has been that patients with pancreatic cancer are often not diagnosed until it is too late for the best chance at effective treatment,” Dr. Robert Vonderheide, director of the Abramson Cancer Center at the University of Pennsylvania, said. “Having a biomarker test for this disease could dramatically alter the outlook for these patients.”

The best candidate biomarker was plasma thromospondin-2. It was screened against 746 cancer plasma samples and control samples using a cheap, commercially-available protein-detection assay.

The researchers found that blood levels of THBS2 and levels of a later-stage biomarker, CA19-9, was a reliable way to detect the presence of pancreatic cancer. They refined the detection method with assessments of samples from patients with various stages of cancer.

The team also reported that the combination biomarker panel was able to help distinguish cases of pancreatic cancer from pancreatitis.

“Positive results for THBS2 or CA19-9 concentrations in the blood consistently and correctly identified all stages of the cancer,” Zaret said. “Notably, THBS2 concentrations combined with CA19-9 identified early stages better than any other known method.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Diagnostics, Featured, Oncology, Research & Development Tagged With: University of Pennsylvania

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS